ULTIMOVACS ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.89 NOK | +10.16% |
|
+26.46% | -92.76% |
| May. 07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | - | Sales 2025 * | 87M 8.27M | Capitalization | 278M 26.4M |
|---|---|---|---|---|---|
| Net income 2024 * | -147M -13.98M | Net income 2025 * | -72M -6.85M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 334M 31.71M | Net cash position 2025 * | 287M 27.29M | EV / Sales 2025 * | -0.11 x |
| P/E ratio 2024 * |
-3.36
x | P/E ratio 2025 * |
-7.46
x | Employees | 26 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ultimovacs ASA
More recommendations
More press releases
| 1 day | +15.24% | ||
| 1 week | +32.29% | ||
| Current month | +33.24% | ||
| 1 month | +33.62% | ||
| 3 months | -93.09% | ||
| 6 months | -91.76% | ||
| Current year | -92.43% |
1 week
7.00
9.31
1 month
6.579.31
Current year
6.07165.00
1 year
6.07178.60
3 years
6.07178.60
5 years
6.07178.60
10 years
6.07178.60
| Managers | Title | Age | Since |
|---|---|---|---|
Carlos de Sousa
CEO | Chief Executive Officer | 66 | 20-05-31 |
| Director of Finance/CFO | 57 | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jónas Einarsson
CHM | Chairman | 67 | 11-01-25 |
Henrik Schüssler
BRD | Director/Board Member | 61 | 14-12-31 |
Kari Grønås
BRD | Director/Board Member | 59 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 8.89 | +10.16% | 987 173 |
| 24-05-28 | 8.07 | +12.87% | 973,546 |
| 24-05-27 | 7.15 | -0.28% | 128,704 |
| 24-05-24 | 7.17 | +1.99% | 195,347 |
| 24-05-23 | 7.03 | 0.00% | 309,272 |
Real-time Oslo Bors, May 29, 2024 at 07:21 am EDT
More quotes
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
8.07
NOK
Average target price
6.5
NOK
Spread / Average Target
-19.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -92.43% | 26.49M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +36.64% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- ULTI Stock
